Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor.
about
The therapeutic potential of cannabis and cannabinoidsHigh Times for Painful Blues: The Endocannabinoid System in Pain-Depression ComorbidityThe role of endocannabinoids system in fatty liver disease and therapeutic potentialsPathways in the diagnosis and management of diabetic polyneuropathyDiabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments.Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III.Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system.The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complicationsNovel insights on diagnosis, cause and treatment of diabetic neuropathy: focus on painful diabetic neuropathySingle dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability.Targeting inflammation as a treatment modality for neuropathic pain in spinal cord injury: a randomized clinical trialPlasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.Role of the endocannabinoid system in diabetes and diabetic complications.Subjective and physiological effects after controlled Sativex and oral THC administration.Measures of health-related quality of life in diabetes-related foot disease: a systematic review.Is there any clinically relevant cannabinoid-induced analgesia?Marijuana: modern medical chimaera.Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy.Use of natural compounds in the management of diabetic peripheral neuropathy.Dronabinol and chronic pain: importance of mechanistic considerations.Understanding and treating painful diabetic neuropathy: time for a paradigm shift.Medical cannabis: considerations for the anesthesiologist and pain physician.An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain From Spinal Cord Injury and Disease.Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke.Cannabis and Cannabinoids for Chronic Pain.A drug discovery case history of 'delta-9-tetrahydrocannabinol, cannabidiol'.Cannabis use and oral diseases.Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings.The contributors of emotional distress in painful diabetic neuropathy.Activation of cannabinoid receptor 2 attenuates mechanical allodynia and neuroinflammatory responses in a chronic post-ischemic pain model of complex regional pain syndrome type I in rats.
P2860
Q24600806-B38E9FA7-63C9-4A89-BE3C-2DB102F72BA5Q26784030-EC1602ED-66D0-4F8D-8C79-68F6F146C49FQ27009466-80B5E223-0BC2-4F54-B994-CD9483BBEBE7Q28082465-0DD1A1A7-01CE-4FFB-AE9A-E463B3B5FF0AQ34153575-C90222D2-8550-40BF-9A39-2C097DFF3455Q34173104-8683C1E1-1F0F-43B3-8137-53D76EC5A25AQ35907148-01D3A30A-F69E-4095-A6AB-4FC1F24FE8BFQ35951992-8DC58CD2-7056-4644-8362-AD83A844D7BEQ36329924-DF206C42-3342-4887-A30B-C920877C5026Q36618089-BBC133AF-23B2-4DDD-A2A4-06EAA69CECFFQ37018248-7BEB2CC5-61F8-4AB6-9AAE-273F4949E931Q37029488-B3493125-3B18-43AA-B354-5E6F0D20D8B5Q37085532-67B83742-A924-411F-B22A-DCE5D6664EA1Q37331676-7FCF30BF-AE92-4D3D-A03C-94769E15EE78Q37975938-7F8B3F73-0708-4356-84ED-3D2A0D5DE607Q38003023-49700E23-4C76-4C38-8C78-EE25C07CA177Q38032847-4F249173-D61F-4817-A70A-A2A297238867Q38093664-05BABC6C-2A57-442E-AEEF-07067BF082C3Q38194034-E02B27B6-B2D4-4470-8844-064F683AFC7CQ38211191-082FEAB1-C7FB-4A90-99D3-E34F8631F5C4Q38394422-7FCBF0F3-0CFD-4F65-BA6E-EDD0299DF9F8Q38724380-17B394DA-5EDE-4DD5-9A4C-C26B02194E58Q38855100-A272F905-9548-4DED-84B4-B3E3D82A9CDAQ38974387-0A5D588A-DDEA-458D-A826-2FF88688F025Q43075872-4D67ED58-2194-4737-A875-3330497E64F3Q44830885-36C1A3CB-8763-4615-A09F-E20DF6B1676AQ45009787-8A52C3B6-52A8-426D-8C30-FE84ABF133ECQ47958585-FD368114-56E4-49B2-8843-0E728EA25DAFQ48295763-814DE22D-0546-4236-88F3-E817CCEFE0ABQ51417508-DB8C648F-165F-41CB-90E6-AF8FDB4E14C6
P2860
Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Randomized placebo-controlled ...... is a major confounding factor.
@ast
Randomized placebo-controlled ...... is a major confounding factor.
@en
Randomized placebo-controlled ...... nnabis-based medicinal product
@nl
type
label
Randomized placebo-controlled ...... is a major confounding factor.
@ast
Randomized placebo-controlled ...... is a major confounding factor.
@en
Randomized placebo-controlled ...... nnabis-based medicinal product
@nl
prefLabel
Randomized placebo-controlled ...... is a major confounding factor.
@ast
Randomized placebo-controlled ...... is a major confounding factor.
@en
Randomized placebo-controlled ...... nnabis-based medicinal product
@nl
P2093
P2860
P356
P1433
P1476
Randomized placebo-controlled ...... is a major confounding factor.
@en
P2093
Celia J Emery
Dinesh Selvarajah
Rajiv Gandhi
P2860
P304
P356
10.2337/DC09-1029
P407
P577
2009-10-06T00:00:00Z